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Plain Language Summary
ASD is a chronic neurodevelopmental disorder that is increasing in prevalence worldwide.
There are no FDA-approved medications to treat the core symptoms
even though ASD shares many signs and symptoms with other neuropsychiatric
diseases.
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Purpose: Autism spectrum disorder (ASD) is a debilitating neurodevelopmental disorder with
high heterogeneity and no clear common cause. Several drugs, in particular risperidone and
aripiprazole, are used to treat comorbid challenging behaviors in children with ASD. Treatment
with risperidone and aripiprazole is currently recommended by the Food and Drug
Administration (FDA) in the USA for children aged 5 and 6 years and older, respectively.
Here, we investigated the use of these medications in younger patients aged 4 years and older.
Patients and Methods: This retrospective case series included 18 children (mean age, 5.7
years) with ASD treated at the Kids Neuro Clinic and Rehab Center in Dubai. These patients
began treatment with risperidone or aripiprazole at the age of 4 years and older, and all
patients presented with comorbid challenging behaviors that warranted pharmacological
intervention with either risperidone or aripiprazole.
Results: All 18 children showed objective improvement in their ASD core signs and symptoms.
Significant improvement was observed in 44% of the cases, and complete resolution (minimal-to
-no-symptoms) was observed in 56% of the cases as per the Childhood Autism Rating Scale
2-Standard Test (CARS2-ST) and the Clinical Global Impression (CGI) scales.
Conclusion: Our findings indicate that the chronic administration of antipsychotic medica
tions with or without ADHD medications is well tolerated and efficacious in the treatment of
ASD core and comorbid symptoms in younger children when combined with standard
supportive therapies. This is the first report to suggest a treatment approach that may
completely resolve the core signs and symptoms of ASD. While the reported outcomes
indicate significant improvement to complete resolution of ASD, pharmacological interven
tion should continue to be considered as part of a multi-component intervention in combina
tion with standard supportive therapies. Furthermore, the findings support the critical need
for double-blind, placebo-controlled studies to validate the outcomes.
Keywords: risperidone, aripiprazole, antipsychotic, comorbid challenging behaviors
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FDA-approved pharmacological therapies are currently only
indicated for the treatment of comorbid irritability and severe
behavioral issues in children with ASD aged 5 years and older.
In this study, antipsychotic medications, with or without
ADHD medications, were found to significantly improve ASD
core symptoms when used in combination with standard suppor
tive therapies.
We observed complete resolution of core ASD symptoms in
56% of our patient cohort, which is unprecedented in the medical
literature.
Dose optimization for each patient and chronic use are key to
resolving core signs and symptoms.
The potential benefits and risks must be weighed on a caseby-case basis when considering further optimization of
medications to target core symptoms in children with ASD and
comorbid behavioral issues.

Introduction
Autism spectrum disorder (ASD) is a complex neurodeve
lopmental disorder with high heterogeneity.1 In 2013, the
Diagnostic and Statistical Manual of Mental Disorders,
fifth edition (DSM-5), consolidated the four previously
separate categories of autism under the single umbrella
of “autism spectrum disorder.”1 These categories were
autistic disorder, Asperger’s syndrome, childhood disinte
grative disorder, and pervasive developmental disorder not
otherwise specified.1,2 While the symptoms of ASD can
manifest before 2 years of age, they usually become more
apparent between 2 and 3 years of age.1,3 Patients with
ASD are all unique in their presentation; however, the
disorder is characterized by core symptoms that include
impairments in social interaction and communication, as
well as the presence of restricted and repetitive behaviors.1
These symptoms are universal regardless of culture, race,
ethnicity, or socioeconomic group.1 All children with ASD
experience difficulty in developing social, speech, and
behavioral skills. Therefore, early intervention with beha
vioral therapy affords these children with the best oppor
tunity to support healthy development and to deliver
benefits across their life span.2 Pharmacological interven
tions, where needed, are used as an adjunct to support
patients’ function in their daily activities and to treat
comorbid irritability and difficult behaviors.4,5
ASD impairs social skills and autonomy to a variable
and sometimes severe extent. A longitudinal study over 40
years has shown general improvement in symptoms in
young adulthood but poor outcomes in later adulthood.6
Although core domains may improve across the life span,
some symptom subdomains, such as limited interests or
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facial expressions, may remain unchanged over time.7,8
The impact of these long-term deficits on functioning is
severe, with manifestations that can become increasingly
complex later in life.9 In 2018, the Centers for Disease
Control and Prevention (CDC) in the USA determined that
approximately 1 in 59 children is diagnosed with ASD (1
in 37 boys and 1 in 151 girls), with increasing
prevalence year after year.10
Unfortunately, the current evidence-based pharmacolo
gical treatment approach for ASD is limited to the treat
ment and control of comorbid challenging behaviors
only.11 Risperidone and aripiprazole were approved by
the FDA in 2006 and 2009, respectively, to treat irritability
associated with ASD.12,13 The recommended age to initi
ate treatment with these medications is 5 years and above
for risperidone and 6 years and above for aripiprazole. In
randomized controlled trials, risperidone and aripiprazole
have been found to improve irritability and agitation in
children with ASD.14,15 The majority of children with
ASD show improvements in challenging comorbid beha
viors such as irritability, agitation, aggression, self-injury,
and disruptive behaviors when using these medications.16
Both drugs are classified as atypical antipsychotics, and
this class of medication can potentially cause significant
side effects such as sedation, weight gain, and metabolic
disturbances; therefore, close follow-up and monitoring by
a physician with special expertise are required when using
these medications.17 To mitigate medication-induced
weight gain, metformin can be prescribed if needed.17,18
Several medications typically used to treat children with
attention-deficit hyperactivity disorder (ADHD), including
methylphenidate, atomoxetine, guanfacine, and bupropion,
have been reported to also improve hyperactivity and
attention symptoms in children with ASD.19–22
In this retrospective report, we present our singlecenter experience in treating 18 children with ASD and
comorbid behavioral issues. These children were treated
from the age of 4 years and older with risperidone or
aripiprazole, either with or without atomoxetine or methyl
phenidate, combined with standard supportive therapies.
A significant clinical and statistical improvement in the
patients’ core signs and symptoms, in addition to improve
ments in their behavioral issues, was observed as per the
Childhood Autism Rating Scale 2-Standard Test (CARS2ST) and the Clinical Global Impression (CGI) scales.23,24
The Clinical Global Impression-Severity (CGI-S) and
CARS2-ST scale were performed at baseline, and serial
Clinical Global Impression-Improvement (CGI-I) scores
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were obtained to monitor improvement. Once a patient
attained a CGI-I score of 1 or 2 we repeated the CGI-S
and CARS2-ST to further confirm improvement, in addi
tion to serial clinical evaluations and follow-up.

Patients and Methods
Patients
This is a retrospective case series report of all patients,
aged 4 years or older, who were diagnosed with autism
spectrum disorder and comorbid behavioral issues and
treated at our center (Kids Neuro Clinic and Rehab
Center, Dubai) from 2017 to 2020, and for whom
informed consent was obtained from the parents or legal
guardians to participate in this study. The cohort com
prised 18 children in total. The children’s parents and
legal guardians were duly notified of the off-label use
and potential side effects of the antipsychotic medications
used in this study. The data collected for each patient
included: age at presentation, age of initiation of the first
medication, medications used, starting dose, time to reach
the maximum dose, current medications, medication side
effects, analyses performed, initial signs and symptoms,
initial formal diagnosis as per the DSM-5 criteria and
CARS2-ST, baseline CGI-S score before starting medica
tions, Clinical Global Impression-Improvement (CGI-I)
score, and their repeat CARS2-ST as per their last visit
to our clinic.
To supplement the CGI-I scale, we also used the CGI-S
score in addition to CARS2-ST at baseline against which
we marked each patient’s severity prior to starting medica
tions. Condition severity was scored on the following
seven-point CGI-S scale: 1 = normal, not at all ill; 2 =
borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5
= markedly ill; 6 = severely ill; 7 = among the most
extremely ill patients.23
CGI-I is scored on a seven-point scale that compares
the patient’s current condition to their baseline condition
before treatment initiation: 1 = very much improved since
the initiation of treatment; 2 = much improved; 3 = mini
mally improved; 4 = no change from baseline (the initia
tion of treatment); 5 = minimally worse; 6 = much worse;
7 = very much worse since the initiation of treatment.23
CARS2-ST can be used for children aged 2 years and
older and classifies patients into three ASD severity groups
based on a 15-category scoring system: minimal-to-no
symptoms of ASD, mild-to-moderate symptoms of ASD,
and severe symptoms of ASD.5,24,25
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This retrospective observational case series was
approved by an independent Institutional Review Board
(IRB), the Pearl IRB Committee, which is fully accredited
by the Association for the Accreditation of Human
Research Protection Program (AAHRPP; approval no. 20KNRC-101). This study was also approved locally by the
Dubai Healthcare City Regulatory Ethics Committee
(DHCR; approval no. KNCRC-01)

Diagnosis
When a patient with signs and symptoms suggestive of
ASD presented at our clinic, we performed a thorough
history and physical examination. In addition, we per
formed an electroencephalogram (EEG) with a sleep sam
ple to evaluate for electrical status epilepticus in sleep or
epileptic encephalopathy, as well as an auditory brainstem
response (ABR) test to assess for hearing loss. These tests
were conducted to exclude potentially treatable
conditions requiring different treatment approaches.26–29
Pharmacological treatment was recommended if the indi
vidual had a normal ABR, normal EEG, no findings sug
gestive of a genetic disorder (such as dysmorphic features,
a family history of genetic disorders, or an abnormal
genetic test), no global developmental delay, and
a confirmed ASD diagnosis as per the DSM-5 criteria
and CARS2-ST, and a CGI-S score ≥ 4 with comorbid
behavioral issues. In each case, the diagnosis was obtained
by both a pediatric neurologist and a clinical psychologist
following a multidisciplinary assessment and diagnostic
approach. A flowchart of the diagnosis and medication
schedule is depicted in Figure 1.

Treatment
Based on previous safety and efficacy studies recommend
ing atypical antipsychotics for the treatment of the comor
bid behavioral symptoms of ASD, patients were prescribed
either risperidone or aripiprazole.12,13 Risperidone treatment
was usually initiated with 0.25 mg orally at night, and this
dose was increased gradually every 1 to 2 weeks until
reaching either a maximum dose of 2 mg in the morning
and 0.5 mg at night or the maximum dose tolerated by each
patient within these limits (see Table 1 for each patient’s
dosing schedule). This regimen was adhered to as long as
the patient showed improvement with each dose increment
and no side effects. This approach was followed for 8/18
(44%) cases (cases 1, 6, 7, 9, 10, 14, 17, and 18).
Aripiprazole was started at 1 mg at night, and this dose
was increased gradually every 1 to 2 weeks until reaching

submit your manuscript | www.dovepress.com

DovePress

Powered by TCPDF (www.tcpdf.org)

2781

Dovepress

Alsayouf et al

Signs and symptoms suggestive of ASD

yes
No history or physical findings suggestive of genetic disease or global
developmental delay AND normal EEG with sleep sample and normal ABR

Refer for audiology/ENT if
hearing loss is suspected
Treat for ESES or epileptic
encephalopathy if EEG is
consistent with that approach
Consider genetic testing and
referral to geneticist

no

Neuropsychiatric Disease and Treatment downloaded from https://www.dovepress.com/ by 128.163.8.76 on 22-Nov-2020
For personal use only.

yes
Diagnosis: DSM-5 criteria, CARS2-ST, & CGI-S ≥4

After family counselling, start patient on risperidone or
aripiprazole and slowly increase dose

Switch risperidone to aripiprazole or
vice versa and increase dose slowly

Patient shows clinical improvement as per CGI-I scale
with dose increment
Clinical improvement?
yes
no

Continue to increase risperidone or aripiprazole to
maximum dose or maximum tolerated dose

yes
Stop medication

Patient attains CGI-I score of 1 with no excessive
weight gain

no

Add methylphenidate or atomoxetine and increase
dose slowly to maximum tolerated dose

yes

Patient attains CGI-I score of 1 with no excessive
weight gain

yes
Continue medication for at least 6 months after
complete resolution of ASD AND total of 20 months
before any slow trial wean

no
Any signs of ASD recurrence, ADHD, or comorbid
symptoms while weaning
no

yes

Continue to wean
until completely
off medication

Keep on minimum dose to fully
control signs and symptoms and
try to wean again in 6–12
months

Does patient tolerate medication well?
yes

no

Add atomoxetine if on
methylphenidate or
vice versa

Switch patient to
atomoxetine if on
methylphenidate or
vice versa

Patient tolerates added medication with good weight
control and maintains a CGI-I score of 1

yes

Patient tolerates new medication with
good weight control and CGI-I 1

Continue medication until complete resolution of ASD
symptoms for a total of at least 20 months, start
weaning off risperidone or aripiprazole first

Any signs of ASD recurrence, ADHD, or comorbid conditions
no
Wean until completely off
risperidone or aripiprazole, then
wean off methylphenidate or
atomoxetine

yes
Keep on minimum
dose and try to wean
again in 6–12 months

If there are any signs of ASD recurrence or comorbid
conditions while weaning methylphenidate or atomoxetine

no

Stop alternative or added
medications.
If patient continues to have
weight gain, consider
decreasing risperidone or
aripiprazole dose to
minimum effective dose.
If patient improved but
plateaued at CGI-I 2,
continue medication with
regular follow up for side
effects.

Figure 1 Flowchart of the diagnosis and medication schedule.

a maximum dose of 15 mg at night or the maximum
tolerated dose for the patient (Table 1). This regimen was
adhered to as long as an improvement was observed with no
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side effects. This approach was followed for 10/18 (56%)
cases (cases 2, 3, 4, 5, 8, 11, 12, 13, 15, and 16). The
clinical data for all of the patients are provided in Table 1.
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Sex

M

M

M

M

Case

1

2

Neuropsychiatric Disease and Treatment 2020:16

3

4

5; 07/18

4; 02/20

7; 05/19

4; 01/19

Started
(mm/yy)

months.
Atomoxetine 60 mg at night; 7
months.

was added at night after

months.

morning; 8

months.

40 mg at night;
24 months.

Atomoxetine

methylphenidate
36 mg in the

Long-acting methylphenidate
36 mg in the morning; 1 month.

2 months.
Long-acting

Long-acting

months.

was added at night after

15 mg at night;
26 months.

Aripiprazole

was added in the
morning after 17

months.
Atomoxetine 40 mg at night; 7

months.

3 mg at night; 6

Aripiprazole

60 mg at night;
13 months.

Atomoxetine

10 mg at night;
16 months.

Aripiprazole

months.

40 mg at night; 8

months.
Atomoxetine

a day; 19

Normal

Not done

Normal

Normal

Findingsb

Dose;a Total
Duration

Risperidone
0.75 mg twice

Laboratory

Current

methylphenidate 18 mg

Aripiprazole 15 mg at night; 2

night.
Atomoxetine 18 mg

months.

night.

Aripiprazole 2.5 mg at

Aripiprazole 3 mg at night; 2

Aripiprazole 1 mg at

2 months.

Aripiprazole 10 mg at night; 2

2.5 months.

was added at night after
11 months.

night.
Atomoxetine 10 mg

Atomoxetine 40 mg at night;

Atomoxetine 10 mg

Aripiprazole 1 mg at

Risperidone 0.75 mg twice
a day; 11 months.

Reach this Dose

Maximum Dose;a Time to

Risperidone 0.25 mg at
night.

Dose

(Years);
Date

Medication

Medication Starting

Age

Table 1 Clinical Characteristics of All Patients in the Case Series

Not done

Not done

Normal

Normal

Evaluation

Cardiac

continued to be inattentive.

(Continued)

inability to focus.
Long-acting methylphenidate was added as he

Atomoxetine was added for hyperactivity and

atomoxetine was added.

Weight gain on aripiprazole; therefore,

Notes on Medications and Side Effects
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M

6

M

F

5

7

Sex

Case

4; 01/20

6; 11/19

7; 01/17

(mm/yy)

Medication
Started

Date

Age
(Years);

Table 1 (Continued).

1 month.
Risperidone 2 mg in the
morning and 0.5 mg at night;
another 2 months.
Atomoxetine 18 mg at night; 1
month.

night.
Methylphenidate 5 mg
in the morning and
2.5 mg at 2 pm was
added after 1 month.
Atomoxetine 10 mg

Risperidone 2 mg in the
morning and 0.5 mg at night; 3
months.
Atomoxetine 10 mg at night;
from start.

Risperidone 0.25 mg at
night.
Atomoxetine 10 mg
was added at night after
2 months.

was added at night after
another 2 months.

Risperidone 0.5 mg twice a day;

Risperidone 0.5 mg at

10 mg at night, 5
months.

Atomoxetine

0.5 mg at night; 8
months.

morning and

Risperidone
2 mg in the

months.

18 mg at night; 6

10 months.
Atomoxetine

0.5 mg at night;

2 mg in the
morning and

Risperidone

Not done

Not done

Not done

months as aripiprazole was out of stock; she
completely regressed. This was continued for

Tried to switch her to risperidone at 24

Methylphenidate made her irritable.

Notes on Medications and Side Effects

Not done

Normal

Atomoxetine was added to augment
attention.

angry; therefore. it was stopped after 1 week.

therefore, methylphenidate was added.
Methylphenidate made him very irritable and

Risperidone was making him sleepy;

attention.

and she started to self-talk with poor

aripiprazole.
Trial wean of aripiprazole made her anxious

months.

Normal

Cardiac
Evaluation

2 weeks only then she was put back on

month. It was then stopped.
Aripiprazole 5 mg; 8 months.

2.5 mg at 2 pm.
Aripiprazole 2.5 mg was

5 mg at night; 43

Aripiprazole

Laboratory
Findingsb

month.

morning and 2.5 mg at 2 pm; 1

Duration

Current
Dose;a Total

added at night after 1

Methylphenidate 10 mg in the

in the morning and

Maximum Dose;a Time to
Reach this Dose

Methylphenidate 5 mg

Medication Starting
Dose
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M

F

10

11

M

M

9

12

M

8

7; 12/19

7; 05/19

10; 06/19

5; 12/18

7; 06/19
months.
Atomoxetine 40 mg at night; 5
months.
Methylphenidate 20 mg in the
morning; 5 months.

night.
Atomoxetine 10 mg
was added at night after
5 months.
Methylphenidate 5 mg

Atomoxetine 60 mg at night; 2
months.

Atomoxetine 10 mg
was added at night after

Aripiprazole 10 mg at night; 4
months.

Aripiprazole 0.5 mg at
night.

months.

months.

10 mg at night; 9

Aripiprazole

months.

Methylphenidate
10 mg in the

15 months.

morning; 6

morning; 1 month.

was added at night after
7 months.
was added in the
morning after another 3

Methylphenidate 10 mg in the

Atomoxetine 10 mg

Aripiprazole
10 mg at night;

60 mg at night; 7
months.

Atomoxetine

0.5 mg at night;
13 months.

morning and

Risperidone
2 mg in the

a day, 22 months.

Risperidone
1.25 mg twice

months.

morning; 9

Methylphenidate
20 mg in the

10 mg at night;
15 months.

Aripiprazole

Methylphenidate 5 mg

Aripiprazole 10 mg at night; 7
months.

Aripiprazole 1 mg at
night.

8 months.

months.

at night.

a day; 8 months.

started at night after 7
months.
Risperidone 2 mg in the
morning and 0.5 mg at night; 8

Risperidone 1.25 mg twice

Risperidone 0.5 mg was

Risperidone 0.75 mg in
the morning and 0.5 mg

Risperidone 1.5 mg at night; 5
months.

Risperidone 0.25 mg at
night.

was added in the
morning after 7 months.

Aripiprazole 10 mg at night, 5

Aripiprazole 1 mg at

Not done

Normal

symptoms of
hyperprolactinemia.

no clinical signs or

Prolactin was
elevated 10-fold with

symptoms of
hyperprolactinemia.

clinical signs or

Prolactin was mildly
elevated with no

Normal

Normal

Normal

Not done

Normal

Not done

made her irritable.

(Continued)

medications.
Atomoxetine was stopped after 1 week as it

month as her family was not willing to use

She was prescribed risperidone 2 years prior
to visiting our clinic but used it only for 1

night, when first visiting our clinic.

He was already using risperidone for 6
months, 0.75 mg in the morning and 0.5 mg at

medication side effects.

1.5 mg at night as she was concerned about

Risperidone was stopped for 2 months by the
patient’s mother after reaching a dose of

stopped.

irritated on atomoxetine 40 mg. He was on
atomoxetine for a total of 5 months, then

Methylphenidate was added as patient got
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M

M

14

15

M

M

13

16

Sex

Case

4; 04/18

5; 02/19

4; 03/17

4; 03/19

(mm/yy)

Medication
Started

Date

Age
(Years);

Table 1 (Continued).

morning and 0.5 mg at night; 16
months.
Four months after reaching full

visit.

morning; 2 months.
Aripiprazole 10 mg at night; 6
months.
Atomoxetine 40 mg at night; 4
months.

in the morning.
Aripiprazole 1 mg was
added at night after 2
months.
Atomoxetine 10 mg

13 months.
Atomoxetine 60 mg at night; 14
months.
Aripiprazole 6 mg at night; 5
months.

night.
Atomoxetine 10 mg
was added at night after
5 months.
Aripiprazole 2 mg was
months and risperidone
was stopped.

added at night after 16

Risperidone 0.5 mg twice a day;

Risperidone 0.25 mg at

another 5 months.

was added at night after

Methylphenidate 10 mg in the

Methylphenidate 2.5 mg

the morning.

restarted at risperidone 1 mg in

dose the family ran out of
medication, so he was

Risperidone 2 mg in the

0.1 mg twice a day for 3
months prior to his first

months.

Already on risperidone

Aripiprazole 9 mg at night; 10

night.

Maximum Dose;a Time to
Reach this Dose

Aripiprazole 1 mg at

Medication Starting
Dose

6 mg at night; 12
months.

Aripiprazole

60 mg at night;
23 months.

Atomoxetine

40 mg at night;
15 months.

Atomoxetine

10 mg at night;
19 months.

Aripiprazole

months.

0.75 mg in the
morning; 37

Risperidone

months.

9 mg at night; 17

Aripiprazole

Duration

Current
Dose;a Total

Normal

Normal

Normal

Normal

Laboratory
Findingsb

Not done

Normal

Normal

Normal

Cardiac
Evaluation

and augment attention.

night.
Atomoxetine was added to control appetite

target of 2 mg in the morning and 0.5 mg at

continued to gain weight on risperidone and
we were not able to increase the dose to the

Patient was switched to aripiprazole as he

continued to be hyperactive.

Atomoxetine was added because he

this was stopped and replaced with
aripiprazole.

Methylphenidate made him hyperactive, so

Currently off medication

Notes on Medications and Side Effects
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Notes: aAll medications were given orally. bComplete blood count, electrolytes, liver enzymes, kidney function test, lipid panel, hemoglobin A1c, and prolactin.
Abbreviations: ASD, autism spectrum disorder; CGI-I, Clinical Global Impression-Improvement scale; F, female; M, male.
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25 mg at night,
16 months.

Atomoxetine
months.
visit.

morning and
0.75 mg at night.
months.
Atomoxetine 25 mg at night, 2
atomoxetine 18 mg at
night prior to her first

1.75 mg in the
morning and 0.75 mg at night, 7
0.75 mg twice a day and

Risperidone
Risperidone 1.75 mg in the
Already on risperidone

F

8; 09/19

months.
3 months.

months.

as it made her irritable.
Atomoxetine 18 mg at night; 2
Atomoxetine 10 mg
was added at night after

Atomoxetine
18 mg at night; 6

morning; 1 week then stopped
morning after 3 months.

10 months.

Normal

Not done

attention. Tried for one week then stopped as
it made her irritable.

weight gain on risperidone and to augment

with us.
Methylphenidate was later added because of

This was stopped after her first consultation

months.
Methylphenidate 5 mg in the
Methylphenidate 2.5 mg
was added in the

morning and
0.5 mg at night;

morning and 0.5 mg at night; 3
night.

1 mg in the

Risperidone 1 mg in the
Risperidone 0.25 mg at

Risperidone

Normal

Not done

Ethosuximide was given before visiting us.
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When a patient tolerated risperidone or aripiprazole
with no side effects and showed progressive improvement
to a CGI-I score of 1 or 2, the child was continued on that
medication. If the CGI-I score plateaued at 2 or higher, or
the patient started to gain excessive weight and still exhib
ited hyperactivity or an inadequate attention span, methyl
phenidate or atomoxetine was added in an effort to
augment improvement to a CGI-I score of 1, improve
their attention span, and control excessive weight gain
(these classes of medication are known to suppress appe
tite). All children with progressive weight gain were also
referred to a nutritionist since progressive weight gain can
cause serious health issues and may affect compliance
with therapy and lead to the premature tapering of the
medication.
Methylphenidate was usually added at 2.5 mg in the
morning and increased gradually to a maximum dose of
20 mg in the morning or less as tolerated. Atomoxetine
was usually added at 10 mg at night and increased gradu
ally to a maximum dose of 60 mg at night or less as
tolerated, as long as no side effects were observed and
an improvement was seen with each dose increment (Table
1). Once a patient reached a CGI-I score of 1 and a repeat
CARS2-ST score of minimal-to-no symptoms of ASD, we
continued the medications for an additional 6 months
before trying to wean the child very slowly off the med
ications (Figure 1 describes the process used for weaning).
Before the initiation of therapy, a complete blood
count, kidney function test, and lipid panel were per
formed, and the levels of electrolytes, liver enzymes,
hemoglobin A1c, and prolactin were determined to pro
vide a baseline for monitoring any metabolic side effects
of the antipsychotic medications.30–34 The tests were
repeated 3 to 6 months after initiating medication, fol
lowed by subsequent yearly checkups. Similarly, cardiac
evaluations to monitor for any adverse medication effects,
including an echocardiogram and electrocardiogram, were
obtained by a fully trained pediatric cardiologist for half of
the patients 9/18 (50%) when the maximum dose was
reached or earlier if clinically indicated.35–37 Serial mea
surements of weight, body mass index (BMI), height, and
vital signs were obtained for each patient at every office
visit.
The initial presenting and current signs and symptoms
of each patient, initial and current CARS2-ST scores,
initial diagnosis as per the DSM-5 criteria, baseline CGIS score, and current CGI-S and CGI-I scores are described
in Supplementary Table S1.
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All patients were strongly advised to continue the
standard supportive therapies, such as applied behavior
analysis (ABA) therapy, speech therapy, and occupational
therapy. Where a family could not afford these therapies,
the parents and caregivers were provided practical support
and guidance as per our center’s practice. All parents and
caregivers were strongly encouraged to maximize their
child’s opportunity for social interactions by attending
a daycare, nursery, or playgroups, as well as strongly
advised to limit their child’s screen time where applicable.

Statistical Analysis
The statistical significance of the differences between the
mean pre- and post-treatment CGI-S and CARS2-ST
scores was determined with the Wilcoxon signed-rank
test. A P-value < 0.05 was considered statistically signifi
cant. Data were analyzed using the VassarStats online suite
of statistical tools (www.vassarstats.net).

Results
In total, 18 cases of ASD were included in this study,
comprising 14 males and 4 females with a 3.5:1 male-tofemale ratio. The age of the patients at presentation ranged
from 4 to 10 years (mean age 5.7 years). The duration of
treatment ranged from 6 to 43 months (mean 18.3
months). Eight patients (44%) were started on risperidone
and 10 patients (56%) were started on aripiprazole.
Efficacy of treatment was based on the changes in the
CGI-I score from baseline, the repeat CARS2-ST score,
family reports, and clinical observations of the treating
physician.
In total, 10/18 (56%) patients attained a CGI-I score of
1 and had minimal-to-no symptoms of ASD (ie, complete
resolution of ASD symptoms) when reassessed with the
CARS2-ST, while the remaining 8/18 (44%) patients
attained a CGI-I of 2 and a reassessment using CARS2ST showed significant improvement from their baseline
score. The differences in the mean CGI-S and CARS2ST scores pre- and post-treatment in our cohort were
statistically significant (Z = 3.71, P < 0.001 for both)
using the Wilcoxon signed-ranked test, with pre- and posttreatment median values of 5 and 1 for CGI-S, respec
tively, and 35 and 22 for CARS2-ST, respectively.
Among the eight patients who were treated with risper
idone with or without methylphenidate or atomoxetine in
this case series, 5/8 patients (62%) achieved a CGI-I score
of 1 and minimal-to-no-symptoms of ASD when reas
sessed on the CARS2-ST (cases 1, 9, 10, 14, and 18).
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The other 3/8 patients (38%) achieved a CGI-I score of 2
and their repeat CARS2-ST showed significant improve
ment from baseline (cases 6, 7, and 17). Two of the eight
patients (25%) continued with risperidone only and did not
require any adjunct therapy for attention issues (cases 9
and 14).
Among the 10 patients who were treated with aripipra
zole with or without atomoxetine or methylphenidate in
this case series, 6/10 patients (60%) achieved a CGI-I
score of 1 with a normal repeat CARS2-ST (cases 2, 3,
4, 5, 8, and 13), and 4/10 patients (40%) achieved a CGI-I
score of 2 and their repeat CARS2-ST showed significant
improvement from baseline (cases 11, 12, 15, and 16). The
remaining 3/10 patients (30%) did not require any adjunct
therapy to aid attention (cases 3, 12, and 13).
Three patients (cases 2, 16, and 17) showed clear
improvement on monotherapy with risperidone or aripi
prazole to a CGI-I score of 1 or 2 but started to exhibit
excessive weight gain (BMI > 25) with attention deficit;
therefore, atomoxetine or methylphenidate was added. One
patient (case 4) continued to be inattentive on aripiprazole
15 mg and atomoxetine 40 mg at night; therefore, longacting methylphenidate was added in the morning and the
dose was increased to 36 mg. This combination improved
his attention greatly and further improved his CGI-I score
from 2 to 1 with minimal-to-no symptoms of ASD on his
repeat CARS2-ST. One patient (case 16) started to gain
excessive weight with no clear improvement with risper
idone dose increments; therefore, he was switched to ari
piprazole with clear improvement. Two patients (cases 1
and 11) did not tolerate or did not show clear clinical
improvement with atomoxetine as an adjunct therapy and
were switched to methylphenidate with superior results.
Three patients (cases 6, 15, and 17) who did not show
clear improvement on methylphenidate as an adjunct ther
apy or who started to be irritable were switched to ato
moxetine with clear improvement. One patient attained
a CGI-I score of 1 and had minimal-to-no-symptoms of
ASD when reassessed on the CARS2-ST, and he is cur
rently off all medications after being on risperidone for
a total of 37 months (case 14). One patient is on
a maintenance dose only to control symptoms of anxiety
and self-talking, currently attends regular school, and had
minimal-to-no-symptoms of ASD when reassessed on the
CARS2-ST (case 5). All medication regimens are pre
sented in Table 1.
One family stopped risperidone prematurely due to
concerns about medication side effects, and this resulted
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in a clear regression of the patient (case 9) to his original
status. Risperidone was then restarted. The parents of one
patient (case 14) ran out of medication 20 months after
starting risperidone and 4 months after reaching the full
dose of 2 mg in the morning and 0.5 mg at night. The
family noted that during the 4 weeks that he was off
medication, the child became hyperactive again and inat
tentive but did not relapse to his initial ASD symptoms.
That he did not completely relapse may be explained by
the fact that he had already been on risperidone for 20
months, in comparison with case 13, who had only been
on risperidone for 5 months. Of note, one patient (case 5)
completely regressed when she was switched to risperi
done from aripiprazole when aripiprazole was out of stock,
and she was, therefore, placed back on aripiprazole as
soon as it became available again. Another patient (case
18) was already on risperidone and atomoxetine for almost
a year when she presented to us but was still showing
signs and symptoms of ASD. Once the doses were opti
mized, she attained a CGI-I score of 1 and had minimal-tono-symptoms of ASD when reassessed on the CARS2-ST.
Laboratory results for our patients (complete blood
count, electrolytes, liver enzymes, kidney function test,
lipid panel, and hemoglobin A1c) were all within normal
limits for their age. Three patients (17%; cases 9, 10, and
14) developed asymptomatically elevated prolactin levels
and were treated conservatively as per the recommenda
tions of a pediatric endocrinologist. Cardiac monitoring
did not reveal any adverse effects. Some families were
unable to afford cardiac evaluation or unwilling to undergo
it, in which case the patients were monitored clinically for
any signs or symptoms of cardiac issues, but none showed
any adverse cardiac effects.

Discussion
Altered neuronal connectivity and plasticity in the brain
cortex are reported to be the underlying cause for the signs
and symptoms observed in ASD patients.38–41 In mice
with ASD, the prefrontal cortex appears to be the main
site of brain pathology.42–45 Aman et al reported
a considerable improvement in irritability and maladaptive
behavior in comparison to the baseline, including core
symptoms associated with ASD, in ASD patients who
had been treated with risperidone for an average of 21
months.46 Recent studies in mice have shown that the
chronic administration of risperidone or aripiprazole
improves valproic acid-induced social interaction deficits
and recognition memory impairment, with reductions
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observed in dendritic spine density in the prefrontal cortex
and hippocampus.47 In addition, methylphenidate and ato
moxetine were both found to improve valproic acidinduced social deficits and recognition memory impair
ment in mice.48
The financial and social burden of ASD is huge and
expected to rise substantially in the coming years.10 For
example, intensive behavioral interventions for children
with ASD cost from $40,000 to $60,000 per child in the
USA in 2011.49 The lifelong cost of supporting an indivi
dual with ASD and intellectual disability is estimated to be
$2.4 million in the USA and £1.5 million ($2.2 million) in
the UK.50 Residential care or supportive living accommo
dation during adulthood and individual productivity loss
both contribute to these high costs.50 Caring for Americans
with ASD cost society a staggering $268 billion in 2015,
a number that has increased more than six-fold since 2006
and is expected to rise to $461 billion by 2025 in the
absence of more effective interventions and support across
patients’ life spans.10,51 Therefore, finding a successful
treatment for ASD is a global necessity.
For this case series, children who presented with ASD
and comorbid challenging behaviors at our center were
started on the antipsychotics risperidone or aripiprazole
provided their parents or legal guardians agreed with the
treatment plan and understood the off-label use of such
medications. We titrated medication doses to also target
core symptoms and not just control challenging behaviors.
We combined two proven therapeutic approaches, namely
non-biological (eg, ABA therapy) and biological therapies
(risperidone and aripiprazole), to treat children with ASD
in a region where the vast majority cannot afford full
supportive therapies. We added ADHD medications as
needed to further augment attention as attention is crucial
in the learning process. This intervention approach is
based on our initial observations that these medications
improved many aspects of ASD symptoms when used to
control comorbid behavior as indicated by the FDA. We
noted that treating difficult comorbid behavior, anxiety,
poor attention, and hyperactivity made ASD patients
a lot more responsive and receptive to supportive thera
pies. In addition, many previous studies and reports sup
port the use of these medications in young children with
ASD.14–17,19,20 Several studies have shown improvements
in the core symptoms of children with ASD when using
risperidone or aripiprazole, including language impair
ment, maladaptive behaviors, social withdrawal, stereo
typy, sensory motor issues, inappropriate speech, and
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ADHD.52–58 Troost et al, in their placebo discontinuation
study, reported that risperidone helped prevent relapses in
problem behaviors in children with ASD when used for 6
months, and the authors concluded that these results pro
vide a rationale for the continued use of risperidone
beyond 6 months with close observation for weight gain.59
Here, the medication doses were slowly increased to
the maximum dose tolerated and this regimen was main
tained as long as the patient continued to show improve
ment and the maximum allowed dose had not been
reached. If the patient did not respond to risperidone, the
patient was shifted to aripiprazole or vice versa. Patients
who responded initially but then plateaued over subse
quent dose increments were supplemented with atomoxe
tine or methylphenidate to help increase attention, control
hyperactivity, and attain further improvement. Patients
who continued to improve with risperidone or aripiprazole
increments but started to experience side effects, such as
excessive weight gain along with attention deficit and/or
hyperactivity, were also supplemented with atomoxetine or
methylphenidate to control their weight and further
improve their attention span. Our goal was to achieve
a low CGI-I score with minimal-to-no-symptoms of ASD
as per the CARS2-ST and clinical evaluation.
We used the DSM-5 criteria and CARS2-ST to confirm
the diagnosis of ASD. The CGI scale and CARS2-ST were
used to measure baseline severity and to monitor improve
ment. The American Academy of Child and Adolescent
Psychiatry (AACAP), in its 2014 ASD practice para
meters, emphasized that the most important diagnostic
step is clinical diagnosis based on careful consideration
of the DSM-5 criteria.4 These guidelines further empha
size that while there are many assessment instruments for
ASD, including the childhood autism rating scale (CARS)
and the autism diagnostic observation scale (ADOS)
among others, these instruments, if needed, should only
supplement and not replace informed clinical judgment
based on the DSM-5 criteria. The American Academy of
Pediatrics (AAP), in its latest ASD clinical report pub
lished in 2020, emphasized the importance of using the
DSM-5 criteria and definitions for the clinical diagnosis of
ASD.5 Severity ratings of DSM-5 criteria do not provide
a quantifiable score and are based on the extent of the
patient’s social communication impairments, their
restricted and repetitive patterns of behavior, and the resul
tant level of care the individual requires; thus, these ratings
often reflect the impact of cognitive limitations.5,60 In
contrast, the CGI-I scale offers an objective, readily
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understood, and practical measurement tool that can be
easily applied even in a very busy clinical setting. It has
two main features that make it suitable for ASD patients
and treatment trials: there is scope for cross-comparison
with the many other trials in which the CGI-I rating scale
has been used in psychiatry, and it reflects general severity
and clinical improvement even in small ASD studies,
especially when combined with a standard ASD test like
CARS2-ST.60,61 Therefore, in addition to clinical diagno
sis based on the DSM-5 criteria, which also provides
a severity scale, we included CARS2-ST and the CGI
scales to try to maximize sensitivity and specificity in
diagnosis and when monitoring for improvement among
our patients.5,7,60 Diagnosis in each case was made by
a team comprising both a pediatric neurologist and clinical
psychologist.
In this case series, while risperidone or aripiprazole
was started at an earlier age than that recommended by
the FDA to primarily control behavioral issues, the offlabel use of risperidone, aripiprazole, and other psycho
tropic medications is well described in common practice
with a trend of increasing use in recent years, especially in
preschool children with ASD.62–68 Treating our patients
with early and chronic administration of risperidone or
aripiprazole along with standard supportive therapies, sup
plemented with methylphenidate or atomoxetine as needed
to augment attention, resulted in marked and statistically
significant clinical improvement with minimal-to-nosymptoms (resolution of symptoms) of ASD in 56% of
these patients as per the CGI-S scale, CARS2-ST, and
clinical evaluation.
This is a single-center case series of children with ASD
who were treated successfully with the antipsychotic drugs
risperidone and aripiprazole in combination with atomoxe
tine or methylphenidate along with standard supportive
therapies. These medications have been available on the
market for over a decade and have been used to treat
psychiatric disorders that share many features with
ASD.69,70 Recent meta-analyses concluded that patients
with ASD have a high burden of comorbid neuropsychiatric
disorders such as anxiety disorders, depressive disorders,
bipolar and mood disorders, schizophrenia spectrum, suici
dal behavior disorders, attention-deficit/hyperactivity disor
der, as well as disruptive, impulse-control, and conduct
disorders and may share underlying brain circuit disruption
or pathology.69,70 The improvements in symptoms in our
patient cohort are likely due to the following: initiating
risperidone or aripiprazole as soon as a diagnosis was
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made and as young as 4 years to control challenging beha
vior that can be a major barrier for learning, prescribing
medications to control challenging behavior and target the
core symptoms under the assumption that all ASD core
symptoms are neuropsychiatric in nature and need to be
treated the same way, and slowly increasing the medication
doses to the maximum tolerated or highest dose allowed to
achieve significant clinical improvement with an individua
lized treatment plan. These medications need to be used for
many months to result in minimal-to-no-symptoms of ASD
signs and symptoms, and treatment requires combining
antipsychotic drugs with medications used for attention
deficit hyperactivity as needed, to augment attention and
control hyperactivity. This must be performed in a manner
that is tailored to each patient’s response, as attention plays
a critical role in the learning process. Unfortunately, all
double-blind, placebo-controlled studies performed to date
on ASD were of short duration, used medications to pri
marily control challenging behaviors in children with ASD,
did not combine antipsychotic medications with ADHD
medications, and did not include cross-over design for nonresponders.14,15,56,71–78
The main side effects noted were weight gain, sedation,
drooling, and irritability. Sedation and drooling were noted
mainly when first initiating the medications, were mild in
nature, and disappeared with continuation of the medica
tions. This could be related to the very slow titration
schedule we used for our patients. Weight gain was exces
sive, uncontrollable (BMI > 25), and required further
intervention in only five patients (17%).
A major challenge we faced in our approach was to
convince the families to start or continue using the medi
cations once they were duly informed about the side
effects of the medications and their FDA-approved uses.
The findings of this case series are limited because of
the small sample size and retrospective nature of the data
collection. These factors might have caused an inherent
bias in the results. Cardiac evaluations were not performed
for all patients, mainly because of affordability issues or
the families being unwilling.

patients with ASD can be successfully treated and potentially
cured this way. Early intervention with behavioral therapy
and pharmacological medications provide the best opportu
nity to support normal development in children with ASD.
No one medication works for all children, and a trial of other
antipsychotic medications should be used if a patient fails to
respond to the first medication tried. While reported out
comes indicate significant improvement in the core signs
and symptoms of ASD, pharmacological intervention should
continue to be considered as part of a multi-component
intervention in combination with standard supportive thera
pies. The potential benefits and risks must be weighed on
a case-by-case basis when considering the use of medications
to target core symptoms in children with ASD. Double-blind,
placebo-controlled studies should be conducted to verify the
findings of our study. Finding an effective treatment for ASD
is of utmost importance because of its increasing prevalence,
its poorly understood causes and pathology, and its devastat
ing consequences.

Conclusions

Author Contributions

Our study showed clinically and statistically significant
improvement of ASD patients’ core signs and symptoms as
per the CGI scales and CARS2-ST with early and chronic
administration of risperidone or aripiprazole, with or without
ADHD medications, and combined with standard supportive
therapy. Our findings suggest that a notable proportion of
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